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Abstract
Background: The COVID-19 pandemic has challenged healthcare systems around 
the world, where resources have refocused on increasing critical bed capacity to 
prepare for the peak in incidence of COVID-19. Oncology faces an unprecedented 
challenge as patients require multidisciplinary care and are more likely to be immu-
nosuppressed. Services in oncology have been transformed using minimal resources 
over a short period of time. This transformation continues and telemedicine is play-
ing a key role.
Aims: We explore how services in oncology have transformed to deliver services 
including consultations, systemic anticancer therapy, and surgery for patients, while 
shielding them from contracting COVID-19. We assess the risks and benefits of the 
service transformation in the immediate, interim, and long term, and how telemedi-
cine supports the process.
Methods: We performed a comprehensive review of the literature using suitable 
keywords on the search engines of PubMed, SCOPUS, Google Scholar, and latest 
official data from May to June 2020.
Results: Through the published literature on this topic, we discuss the transfor-
mations in oncology and the impact on patients and healthcare workers due to the 
COVID-19 pandemic. We reflect on the lessions from COVID-19 and assess the role 
of telemedicine in the future of oncology services.
Conclusion: Transformation of services in oncology effectively shields patients 
from COVID-19 infections, and telemedicine plays a role in virtual consultations. 
The long-term effects are yet to be seen, such as safety of home-based treatment, and 
effectiveness of virtual communication on patient care. As oncology requires a mul-
tidisciplinary approach, telemedicine will play a key role to improve patient-centered 
cancer care in the future.
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1 |  INTRODUCTION
The emergence of the novel severe acute respiratory syn-
drome coronavirus (SARS-CoV-2) pandemic has become 
a global health challenge, which was firstly discovered in 
China in late 2019.1 Coronavirus disease (COVID-19) causes 
fever, dry cough, dyspnea, loss of smell, and other non-
specific symptoms, meaning it is difficult to differentiate 
COVID-19 from other infectious diseases.2 Due to its high 
transmission risk, it has affected almost six-million people 
causing 382 867 deaths in almost all continents as of 5 June 
2020. And in the United Kingdom (UK), it has claimed over 
39 000 deaths (see Figure 2.) of those 153 807 lab-confirmed 
cases (see Figure 1.).3,4
In response to the COVID-19, the UK government's 
coronavirus action plan was launched in early March and 
initiated a locked down since late March 2020.5,6 The gov-
ernment's plan is to protect National Health Service (NHS) 
from being overwhelmed from the exponential growth in 
COVID-19 confirmed cases. The NHS transformed their ser-
vices to maximize inpatient and critical care capacity to free 
up a target of at least 30 000 beds of the 100 000 beds for 
COVID-19.7 In the immediate period, all services including 
oncological services were impacted while resources were 
refocused on the government's COVID-19 response. At the 
same time, the NHS experienced an unprecedented staffing 
crisis due a significant number of staff being infected and/
or in self-isolation.8,9 Due to the service transformation or 
patients’ personal choice, there was on average a fall of 30% 
of patients receiving chemotherapy and up to 50% fall in new 
patients presenting or referred for suspected cancer diagnosis 
in March to April 2020.7
In the interim period, essential and urgent cancer services 
continued, whereas referrals and other services were post-
poned or transformed to enable virtual delivery.10 Because pa-
tients with cancer are more likely to be immunosuppressed, it 
is important minimize their risk of exposure to SARS-CoV-2. 
Strategies include requiring staff and patients to wear per-
sonal protective equipment (PPE) to prevent viral transmission 
or setting up home delivery of certain systemic anticancer 
therapy (SATs), such as home delivery of tyrosine kinase in-
hibitors (TKIs) or home delivery of Herceptin, given subcuta-
neously.11-13 Home delivery of certain SATs enables patients to 
avoid unnecessary visits to hospitals and reduces waiting time 
for other patients on the chemotherapy suite, thereby allowing 
better social distancing.14 To guide clinicians to make better 
decisions, National Institute for Health and Care Excellence 
(NICE) has developed a triage system to categorize patients 
by their odds of survival from treatment 15 (Table 1). For pa-
tients requiring treatment at hospital, such as surgery, they are 
referred to the newly developed COVID-free cancer hubs for 
procedures to be performed (Table 2). Furthermore, long-term 
effects are unknown, such as the challenge to maintain social 
distancing, safety of prolonged home-based treatment, and 
safety issues surrounding the ability to remotely monitor drug 
toxicities.
The future development of oncological service follow-
ing the COVID-19 pandemic is unknown, but there is an 
increasing demand for virtual medical services—where the 
current technological capabilities remain mostly on tele-
phone consultations in the NHS. Furthermore, it is import-
ant to provide support for healthcare workers’ physical and 
mental health as the NHS plans for the long-term service 
transformation.16
F I G U R E  1  Graph shows total number 
of lab-confirmed cases of COVID-19 in 
the UK by date. It recorded the number of 
confirmed cases from late January to over 
150 000 cases by June 20204
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2 |  COVID-19 
2.1 | Origin and emergence of COVID-19
The phenomenon of coronavirus-based epidemics was first 
seen in 2002-2003 when cases of atypical pneumonia were 
identified in Guangdong Province, China, later spreading 
to Hong Kong where researchers were able to isolate the 
pathogen and classified it as a coronavirus, naming the re-
sulting disease severe acute respiratory syndrome (SARS). 
International travel subsequently spread SARS to a further 
26 countries, resulting in a case load of more than 8000 with 
an approximate 10% fatality rate.17 Another example of a 
coronavirus from an animal origin that resulted in a much 
publicized epidemic is the Middle East respiratory syndrome 
coronavirus (MERS-CoV) which emerged in 2012 and was 
characterized by a much higher case fatality rate, but limited 
human-to-human transmission.18
The initial chronology of the COVID-19 pandemic is con-
troversial, but the following is one of the commonly accepted 
chronology. The first reported cases of the novel coronavirus 
were identified in late December of 2019; from 18 to 29, five 
patients were hospitalized with one case ending in death.1,19 
The origin of the identified cases was epidemiologically 
traced back to the Huanan seafood and wet animal wholesale 
market in Wuhan, Hubei Province, China.20 By 25 January 
2020, cases in the Chinese mainland had progressed to a total 
of 1975 cases and 56 deaths.21
2.2 | Global spread
The World Health Organization (WHO) first declared the 
outbreak of COVID-19 as a Public Health Emergency of 
International Concern (PHEIC) on 30 January 2020,9 further 
recognizing it as a pandemic on 11 March 2020.22
According to the WHO’s latest situation report on 4 June 
2020, the global confirmed case count sits at 6  416  828 
cases and a confirmed death count of 382 867 deaths, with 
confirmed cases in all continents excluding Antarctica; as 
the count reflects only lab-confirmed cases and deaths the 
actual figures for both counts may be significantly higher, 
especially in developing countries where testing is not as eas-
ily accessible and implemented. The United States has the 
highest global count in both confirmed cases and deaths by 
a majority, with the UK following behind in terms of deaths 
but not cases.3,4
2.3 | Epidemiology of COVID-19 in the UK
The first recorded case of COVID-19 in a British national 
is thought to be Connor Reed, a 25-year-old Welsh national 
working at a college in Wuhan, China,23 he remained in 
Wuhan throughout his diagnosis and disease course. In May 
2020, the BBC reported the experiences of Dr John Wright 
of Bradford Royal Infirmary in encountering COVID-19-like 
symptoms in members of a choir in Yorkshire returning from 
a business trip on 17 or 18 December, long before the first 
confirmed cases.24
The first confirmed cases in the UK were diagnosed in the 
week commencing 27 January 2020, both were identified as 
at risk while still in the community and were transported from 
their hotel to the Infectious Diseases Unit at Hull University 
Hospitals where they were managed in separate negative pres-
sure rooms until results were available, after which they were 
transferred to the High-Consequence Infectious Diseases 
Unit (HCID) in Newcastle, UK. The third confirmed case 
was reported on 6 February 2020, a Brighton man who re-
turned from Singapore and France on 28 January.25 By 12 
March, the UK case total had risen to 460,26 which combined 
with the WHO’s PHEIC declaration provoked the escalation 
F I G U R E  2  Graph shows the recorded 
number of deaths from March 2020 to June 
2020 in the UK. It recorded several deaths 
since early March to over 39 000 deaths by 
June 2020 3
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of the risk level in the UK from moderate to High.27 As of 5 
June 2020, the statistics for COVID-19 in the UK are as fol-
lows, 153 807 total lab-confirmed cases (see Figure 1.) and 
39 728 confirmed deaths (see Figure 2.), giving an infection 
fatality rate of approximately 14.1%.3
The UK government's coronavirus action plan was 
launched on 3 March,27 further listing it as a notifiable dis-
ease on 5 March6 and initiating lockdown on the 23 March.5 
As of 30 May, the government is slowly moving back into 
a phase of loosening lockdown restrictions and reopening 
shops, services, and schools in a staggered stage model.28
3 |  COVID-19 AND CANCER
3.1 | Incidence and prevalence
Although the evidence base is limited, a cross-sectional study 
based in Wuhan, China found that a sample size 1524 cancer 
in-patients over a 6-week period had a 0.79% infection rate, 
higher than the 0.37% cumulative incidence in the full hospi-
tal patient community, although all these oncology in-patients 
were in a poor enough condition to warrant admission which in 
itself is a poor prognostic factor for infection risk, as well as the 
fact that community cancer patients were unaccounted for.29
3.2 | Presentation
Clinical characteristics in cancer patients with COVID-19 do 
not differ to the non-cancer population and includes the fol-
lowing and summarized in Table 3.
- Fever
- Dry cough
- Dyspnoea
- Chills
- Muscle pain
- Headache
- Sore throat
- Rigors
- Loss of taste and/or smell 2
Data are limited, however, with most existing studies lim-
ited by small sample sizes. A report consisting of 28 COVID-19 
patients from three hospitals in Wuhan, China showed that the 
most common characteristics were fever, dry cough, lympho-
penia, and anemia with 75%-82% of patients presenting with 
these; 54% of patients had severe disease, and 21% required ICU 
admission; severe events were more common in patients who 
had chemotherapy, radiotherapy, targeted therapy, or immuno-
therapy in the last 14 days; patch consolidation on CT scan was 
associated with greater risk of severe disease.30
3.3 | Prognosis
COVID-19 presents with a higher mortality rate and severity in 
an older population; regardless of age patients with a pre-exist-
ing medical condition are also at increased risk if infected.31,32
Developing data suggest that an increased severity of 
COVID-19 disease course is associated with adult patients 
with cancer.2
T A B L E  1  Prioritization system for patient receiving systemic anticancer treatment
Priority 1 Priority 2 Priority 3 Priority 4 Priority 5 Priority 6
Curative 
treatment
Chance (%) of 
success for 
curative treatment
>50% 20%-50% 10%-20% 0%-10% — —
Adjuvant or 
Neoadjuvant 
treatment
Additional chance 
(%) to cure
>50% 20%-50% 10%-20% <10% — —
Non-curative 
treatment
Chance of 
immediate 
extension of life 
of 1-year or more.
— — >50% 15%-50% >50% (chance 
of palliation or 
temporary tumor 
control)
15%-50% 
(chance of 
palliation or 
temporary 
tumor control)
T A B L E  2  Prioritization system for patient receiving cancer surgery
Priority 1a Priority 1b Priority 2 Priority 3
Type of 
surgery
Emergency—
operation 
needed with 
24 hours to save 
life
Urgent—operation 
needed with 
72 hours
Elective—operation needed within 
4 weeks to save life/progression of 
disease
Elective—can be delayed for up to 
10-12 weeks without having predicted 
negative outcome
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Early data from Wuhan, China in an analysis of 105 pa-
tients whose outcomes were matched with 536 control pa-
tients showed that in the cancer population, Lung cancer was 
the most frequent malignancy followed by gastrointestinal, 
breast, or thyroid, then hematological malignancy; compared 
with the noncancer control population, cancer patients had 
higher death rates, ICU admission rates, a greater likelihood 
of severe symptoms and a doubled chance of requiring in-
vasive mechanical ventilation; however, cancer patients also 
were more often smokers and experienced more in-hospital 
infections, which may have been contributing factors to the 
statistical differences.33
4 |  IMPACT ON ONCOLOGICAL 
SERVICES
4.1 | Immediate impact on oncological 
services
In response to the COVID-19 pandemic, the National Health 
Service (NHS) had experienced an unpresented challenge. 
Over a very short period of time, NHS had to adapt their ser-
vices to meet the demands of the sudden surge of patients 
presented with COVID-19 symptoms. The limited data and 
misinformation had left frontline health workers in frustra-
tion to adapt their services effectively.34
Retrospectively in March 2020, the NHS was hit by one 
of the worst staffing crises.7,8 This was due to several fac-
tors including the global limited access to personal protective 
equipment (PPE), medical supplies, and upsurge of healthcare 
workers suffering from COVID-19.35 The WHO advises to pro-
tect healthcare workers as one of the priorities meant the thresh-
old of a staff required to be in isolation is very low. Any staff 
presenting any symptoms of COVID-19 are required to self-iso-
late.9 This not only had an immediate impact on the service 
capability of the NHS, but also long-term effects on the individ-
ual healthcare worker, which is discussed further below.16 This 
has further been exacerbated by the limited COVID-19 testing 
capacities, which was only at less than 1000 tests performed 
per day in late March.36 Moreover, the NHS experienced one of 
the largest redeployment of staff to redistribute the workforce 
in order to meet the demands of the coronavirus pandemic.37 
Some local oncology teams had seen over half of their team 
redistributed to COVID-19-related duties.
Concurrently, there was a sharp drop in the number of pa-
tients receiving oncological services. Due to the priority to 
maximize inpatient and critical care capacity with targets of 
freeing up over 10 000 hospital beds across England.7 Along 
with similar strategies, it had led to a 30% reduction in pa-
tients receiving chemotherapy, which included both who are 
asked to be shielded from hospitals, and those patients who 
T A B L E  3  Common clinical features in patients with COVID-19 regardless of cancer status, as there is very little data on clinical feature 
incidence specific to the COVID-19 patient population with cancer.
Clinical Features Incidence Study Population Additional Notes
Fever 99% 138 COVID-19 positive in-patients in a 
single hospital in Wuhan, China 29
Fever is not a universal finding on 
presentation, in one study approximately 
20% of patients had a low-grade fever 
of < 38°C,2 and in another study fever 
was present in 44% on admission and 
ultimately 89% during hospitalization.30
Fatigue 70% Limited data on these clinical features
Dry cough 59%
Anorexia 40%
Myalgias 35%
Dyspnea 31%
Sputum Production 27%
Smell and/or taste sensory alterations 64% 202 COVID-19 patients with mild 
symptoms suitable for home 
management in Treviso and Belluno, 
Italy 31
24% of patients (out of total population) 
reported severe sensory loss.31 However, 
these statistics were self-reported and as 
such objective rates of sensory loss may 
be much lower, in another study only 62% 
of the 86 patients who had total lack of 
smell had an objectively measurable loss32
Gastrointestinal symptoms 18% 4243 total patients from a meta-analysis 
of 60 studies, populations ranging 
from China, South Korea, Singapore, 
Vietnam, United States, UK33
Diarrhea (13%), nausea/vomiting (10%), 
abdominal pain (9%)33
The incidence figures therefore cannot be fully applicable to the COVID-19 cancer patient population but can be used as a rough guidance.
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voluntarily postponed their treatment. Due to the suspension 
of certain GP practices, the department experienced a fall in 
over 50% presentation of new patients referred from general 
practitioners.7
4.2 | Impact on services during the 
interim period
Following the immediate period, the NHS swiftly developed 
mechanisms to better balance the services that were targeted 
to fight against the pandemic, but also to retain essential and 
urgent non-COVID services.
In this interim period, the senior leadership of NHS 
Cancer services released a letter in end of March to advise 
on cancer treatment in response to COVID-19 pandemic.10 
The key recommendations included, first, essential and ur-
gent cancer services must continue, and discuss with pa-
tients about risks associated with continuing treatment, 
second, referrals depart from normal practice and that safety 
netting must be in place to allow patients to be followed up, 
and, third, the development of COVID-free hub for cancer 
surgery with a centralized triage system.10 These key pillars 
serve to guide the decision and changes made by Clinical 
Commissioning Groups (CCGs), Hospital Trusts and local 
hospital.
While these changes took place, it allowed an alleviation 
in the shortage of staff as some return to work. Yet, many 
staff members were redeployed to COVID wards, while those 
who are in isolation are encouraged to conduct telephone and 
video consultations with patients. NICE also advises to sup-
port staff who are in self-isolation through frequent contact to 
protect their mental wellbeing.38 Studies have explored that 
self-isolation can lead to making people feeling anxious and 
unsafe, of that like acute address disorder, where it is likely to 
continue following quarantine.16
Like other specialties, care in oncology is delivered with 
consideration of COVID-19: If a patient is not known to have 
COVID-19, NICE has recommended that patients are to at-
tend appointments by themselves without family members or 
carers as this would reduce the risk of contracting COVID-
19. When patients attend their appointment, service providers 
can reduce time spent at the waiting area of the hospital or 
clinic through effective scheduling. Another strategy involves 
asking patients to wait outdoors or in their cars and inform 
them text if application when the Doctor or healthcare worker 
is ready to see them.11
At our local oncology department, the wards are divided 
into two types, where one is for those patients who are free of 
COVID-19, and the other wards is for those patients who are 
confirmed or suspected to have COVID-19. Staffing is also 
managed to ensure there is no mixing between the clean and 
dirty teams.
Significant interim changes were implemented to 
allow for greater flexibility with the aims to maximiz-
ing benefits and minimizing risks to patients. SATs can 
be administered at home or similar setting that reduces 
patient's exposure to SARS-CoV-2. In our department, 
we applied a similar principle to reduce the number of 
required visits by prescribing every four weeks, instead 
of fortnightly, treatment of durvalumab for patients with 
non-small lung cancer. This is a suggested protocol from 
NHS England even though durvalumab is only licensed 
for up to fortnightly dose.12 This strategy reduces the 
frequency of visits to hospital, in attempt to reduce risk 
of exposure to the virus. Another recommendation is to 
stop maintenance chemotherapy, usually given in com-
bination with maintenance immunotherapy, and allowing 
only immunotherapy to continue.12 This may potentially 
reduce efficacy but improve safety and similarly reduce 
the risk of toxicity and in turn risk of infection and avoid-
able hospital visits. Alternatively, chemotherapy has been 
also recommended to switch to oral therapy to be admin-
istered at home, again this reduces the frequency of hos-
pital visits.12 However, there is conflicting evidence on 
immunotherapy, as some argue it mitigates with patients’ 
risks of contracting the virus or becoming serious ill from 
COVID-19, with exceptions to ibrutinib and a tyrosine 
kinase inhibitor.13
Another common practice includes prescribing prophy-
lactic daily granulocyte-colony stimulating factor (G-CSF) to 
prevent the risk of neutropenic fever, thereby reducing ad-
missions. This has been in practice in our local department 
since late March 2020.12 Other changes in oncology treat-
ments developed by the National Comprehensive Network 
may help guide other oncological departments in their ser-
vice adaption.39
If a patient is known or suspected to have COVID-19, 
patients are advised to follow the most update to date gov-
ernment guidelines on social distancing and self-isolation. 
Unless treatment is deemed to be urgent and essential, 
then patient would be offered to continue with treatment. 
Otherwise, it is recommended that these patients defer all an-
ticancer treatment until at least one negative test according 
to NICE.40 This contrasts with most other recommendations 
which generally suggest a minimum period of 14 days from 
COVID-19 symptom onset or relocation of treatment from 
hospital to home.41
4.3 | Prioritizing patients and centralized 
triage systems
If resources in NHS become scarce in this COVID-19 pan-
demic, it is important to develop clear guidance and a sys-
tem to prioritize patients based on clinical need. It is also 
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important to develop effective pathways to allow for rapid 
and efficient triage of patients down the correct diagnostic 
and treatment pathways. This system should only be used 
if resources become extremely limited, and decision has to 
be made to allocate resources to those patients who are in 
most need - otherwise patients should be provide all available 
treatment options. Summary of the algorithm is illustrated in 
Figure 3.
For SATs, NICE developed a six-tier system to classify 
patients who require SATs to aid clinicians to make the most 
appropriate decisions.15,42 Details of the prioritization sys-
tem can be found in Table 1. For example, though a patient 
with metastatic cholangiocarcinoma considering SATs would 
fall into priority category 4 or 5.15 However, if the patient is 
fit and well prior to the cancer diagnosis, he may well want 
to consider SATs and may not have the opportunity to defer 
treatment for 6  months due to the potential risk of a rapid 
deterioration in symptoms and quality of life. A clear and in-
formed decisions need to make with the patient as to the ben-
efits and risks of starting palliative chemotherapy. Surgical 
services smilarly had to adopt in order to cope with the pres-
sures of COVID-19 infected patients, including orthopaedics, 
cardiac and cancer surgery.43,44 For patients requiring cancer 
surgery, NICE has developed a similar categorization system 
to aid surgical decision and planning.42 Details are illustrated 
in Table 2.
Furthermore, these guidelines are to be implemented with 
consideration of patient priorities as well as the hospital or 
system's priorities. Similar systems have developed in differ-
ent countries with similar principles to reduce risk of infec-
tion and optimize oncological treatment options for patients. 
This is paramount of support the patient's emotional wellbe-
ing by providing psychological support as well as the medical 
care they require.
4.4 | Long-term impact on 
oncological services
The implications on COVID-19 on the world are unprece-
dented and have created novel challenges that all healthcare 
systems around the world must face. There will clearly be 
long term and permanent changes that will be made to shape 
how we practice medicine in the future.
One of the major challenges is to maintain social dis-
tancing, which is likely to stay as a government advice for 
months and even years to come. This poses a challenge to 
face-to-face healthcare delivery. The maintenance of social 
distancing may not be possible in various settings, such as 
in waiting rooms and when performing common procedures. 
This will also be a challenge as those requiring frequent visits 
to hospital are often also those who are clinically extremely 
vulnerable.44
An effective strategy that permits access to services while 
shielding these vulnerable patients is a priority of oncolog-
ical teams across the NHS. As highlighted earlier, staff has 
been encouraged to conduct more virtual practice; however, 
despite the recent initiatives to digitize services, the NHS re-
mains decades behind in its technological capabilities.45 In 
our oncology department, telephone remains the only option 
for virtual consultations, while online conferencing software 
are available on most Trust computers—the department does 
not have access to any webcam nor any audio devices, such 
as headphones.
While the NICE Guidelines recommend interim adapta-
tion of anticancer treatments, it is likely these may implement 
for an extended period, or reintroduced for any subsequent 
coronavirus outbreaks, which is highly likely during win-
ter. Limited evidence is available on the risks and toxicity 
of these interim treatment regimes. This leaves a challenge 
for clinicians who will need to be able to weigh up the best 
treatment options based on limited data and their own clinical 
experience in order to best guide patients along their treat-
ment pathways. This is a clear need and emphasis to move 
treatment to home-based settings, there are raising concerns 
on patient safety, as monitoring toxicities from treatment will 
have to be done more remotely. Delivery of home SATs cer-
tainly has its benefits but is not without challenges, and the 
advent of the global pandemic has expedited these changes 
into clinical practice, but it will certainly require close moni-
toring to ensure there is no increased risks to patients’ health 
and wellbeing.
Another significant impact that is expected to happen with 
cancer services are the backlog of referrals that were delayed 
or interrupted due to the onset of the pandemic. For example, 
at our local cancer center, it is estimated that there are around 
2000 outstanding endoscopies (for suspected gastro-esoph-
ageal cancers) had been requested prior to and during the 
pandemic. With a conversion rate of around 6% to a cancer 
diagnosis for these referrals, this equates to an approximately 
120 potential cancer patients who will receive a cancer di-
agnosis in the near future and require treatment.46 There are 
also the cohort of patients who have developed symptoms 
which are suspicious of cancer during the pandemic but have 
not yet presented to hospital due to concern of COVID19 in-
fection. Further work needs to be done to increase education 
and public awareness and to encourage patients to attend hos-
pital should they feel unwell, least these patients present too 
late to be able to receive a diagnosis and treatment.
5 |  SERVICES ADAPTATIONS 
AFTER COVID-19 ERA
From the experiences and challenges that NHS both as an 
organization and as individual staff have faced during the 
COVID-19 pandemic, several lessons can be learnt that would 
help in the modernization and optimization of the NHS.
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There has been a widespread implementation of telemedi-
cine with a dual purpose of compromising for the lack of face-
to-face appointments, as well as optimizing resources where 
redistributing to where it is most needed—in handling the pan-
demic.47,48 What we can learn from this experience is that the 
benefits of telemedicine that we have found during this period 
could also be applied during a time period where COVID-19 
is not present. The use of virtual consultations would allow pa-
tients that, after triage were determined to be of lower urgency, 
to be seen and have any concerns addressed in a much more 
time and resource efficient manner, and in turn free up those 
resources for use of patients with a higher urgency issue while 
F I G U R E  3  Flow diagram shows 
the treatment pathways and algorithm for 
patients receiving oncology services during 
COVID-19 pandemic. Recommendations 
provided by National Institute for 
Health and Care Excellence (NICE) and 
National Comprehensive Cancer Network 
(NCCN)11,12,38,39
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also addressing the longstanding problems of over-booking, de-
layed, and rescheduled appointments 49.
The pandemic has expedited the implementation of many 
systems in order to reduce the burden on the NHS and to comply 
with social distancing guidelines, examples of which are tele-
medicine and virtual clinics mentioned above, as well as work-
from-home set ups for clinicians. This reflects a prioritization of 
resource allocation that was needed to achieve this, from which 
we can also extend to the post-COVID era in order to streamline 
and optimize the logistical infrastructure of the NHS.
While the importance of the mental health of health-
care workers has come increasingly into the spotlight in 
recent years, the COVID-19 pandemic has further high-
lighted the need for adequate support as healthcare workers 
are severely overworked and exposed to an unprecedented 
level of stress. This can be due to pure physical and men-
tal exhaustion, handling many patient deaths as well as the 
gap in supply and demand causing difficult decisions in 
resource allocation to patients, causing moral injury.16,50 
Sufficient support during the pandemic is sorely needed as 
well as adequate after care to prevent staff burnout and pos-
sible instances of survivor's guilt, to form a “meaningful 
rather than traumatic narrative”.51 The increased awareness 
from this period will also serve to encourage clinicians 
and healthcare staff to seek mental health support as well 
as hopefully serving to advance the existing staff mental 
health support infrastructure.
6 |  LESSONS FROM COVID-19
In the specific case of the future optimization and adapta-
tion of oncological services using lessons learned during the 
COVID-19 era, the previous aforementioned implementation 
of telemedicine is particularly relevant as many of the oncol-
ogy department's patients are immunosuppressed and vulner-
able to infection,52 and this would also extend to a COVID-19 
absent setting, if at a lesser severity due to treatment and the 
nature of cancer as a disease.53
Beyond infection risk, many patients can be suffering 
from frailty and severely reduced mobility, making the re-
duced need for transport a relief, both on the patients and on 
the health service as an area of resource drain.
The remote delivery of cancer treatment and patient mon-
itoring can also be carried over to the post COVID-19 era to 
optimize patient wellbeing as well as the psychological and 
mental health benefits of reduced hospital visits.54
These transformations are not without their limitations. 
Telemedicine while providing convenience and resource 
optimization in some areas, is limited in its ability to match 
certain aspects of in-hospital, person-to-person clinics, in-
cluding physical examination, establishment of patient-clini-
cian rapport on the basis of body language as well as staff 
team relationships and teamwork utilization.45 Remote deliv-
ery of services also limits the patient's options of treatment 
and may increase NHS resource drain in certain cases. For 
the adaptations the NHS has made during the COVID-19 era 
to continue to benefit service, clinician, and patient, these 
limitations must be explored and overcome.
Weaknesses of the existing system have also been exposed 
by the strain of the pandemic. While some have been compen-
sated for by remote service delivery, others such as the delay of 
referrals and investigations have not been. In oncology, where 
diagnosis and treatment are extremely time sensitive due to 
progression of disease, improved methods of screening, both 
clinicians executed or patient executed, must be developed and 
implemented. These could be as simple as increased education 
on cancer symptom monitoring and self-assessment or could 
extend to changed protocol in carrying out investigations to en-
sure a minimized infection risk for vulnerable patients.
7 |  CONCLUSION
The COVID-19 pandemic had transformed the oncological 
services by the principle of patient safety by shielding patients 
from contracting the virus and spreading to others. This con-
tinuing service transformation can be achieved by moving ser-
vices into virtual format or home-based treatment. The current 
access to technology is low that would need a radical change 
to improve communications with patient. Oncology is multi-
disciplinary by practice; therefore, many aspects of the ser-
vice remains only possible or most optimally delivered though 
face-to-face.
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